Insys Therapeutics, Inc.
INSY
INSY was delisted on the 18th of June, 2019.
110 hedge funds and large institutions have $84M invested in Insys Therapeutics, Inc. in 2018 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 24 increasing their positions, 37 reducing their positions, and 18 closing their positions.
6% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 18
2% less funds holding
Funds holding: 112 → 110 (-2)
14% less call options, than puts
Call options by funds: $3.29M | Put options by funds: $3.82M
35% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 37
51% less capital invested
Capital invested by funds: $170M → $84M (-$86.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$3.04M |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$957K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$792K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$629K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$570K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$15.6M |
| 2 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$14.2M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$4.18M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.21M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.21M |
INSY Hedge Fund Activity: Q1 2018 in Review
110 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q1 2018, worth a combined $84M — down 51% from $170M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of INSY and 17 opened new positions — a net loss of 1 holder — while 37 trimmed existing stakes and 24 added.
The largest buyer was ETF Managers Group, adding an estimated $3.04M. The largest seller was OrbiMed, cutting an estimated $15.6M.
- 110 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q1 2018, down from 112 in Q4 2017.
- Funds reported $84M of Insys Therapeutics, Inc. stock for Q1 2018, down 51% quarter-over-quarter.
- 17 funds opened new Insys Therapeutics, Inc. positions in Q1 2018 and 18 closed out, a net change of -1 holder.
- The largest Insys Therapeutics, Inc. buyer in Q1 2018 was ETF Managers Group, an estimated $3.04M added.
- The largest Insys Therapeutics, Inc. seller in Q1 2018 was OrbiMed, an estimated $15.6M sold.
Based on aggregated 13F filings for Q1 2018.